Abstract
Objective To study the effects of 2A-1-1, a purified component from Panax notoginsengs which is considered to be a blocker of ROC (Receptor-operated Ca2+ channel), on platelet aggregation in hypertension patients with Nifedipine and 1-{β-[3-(4-methoxyphenyl) propoxy]- 4-methoxyphenethyl}- 1H - imidazole hydrochloride (SK and F96365) in contrast.Methods Platelet rich plasma (PRP) was made in routine way from venous blood samples which taken from 30 essential hypertension patients and 30 normal people. PRP was incubated with different concentrations of 2A-1-1, Nifedipine and SK&F96365 for 3 minutes. Therefore, maximal platelet aggregation rate (PAGmax) induced by ADP had been measured on TYXN-91 aggregometer.Results 1. PAGmax in essential hypertension group was 88.48±5.36%, higher than that in normal group which was 67.54±8.46%( P<0.01). 2. Nifedipine (10μmol/L and 20μmol/L) had no effect on PAGmax in neither essential hypertension group nor normal group( P>10;0.05). 3. 2.5μmol/L, 5μmol/L, 10μmol/L and 20μmol/L SK&F96365 could reduce the PAGmax in essential hypertension group by 14.32%) 17.9%) 30.26%) 78.23% respectively; 5μmol/L, 10μmol/L and 20μmol/L SK&F96365 could reduce the PAGmax in normal group by 21.57%) 22.85%) 59.38% respectively. 4. 2.5μmol/L, 5μmol/L, 10μmol/L and 20μmol/L 2A-1-1 could reduce the PAGmax in essential hypertension group by 24.83%) 27.56%) 48.73%) 92.77% respectively; 5μmol/L, 10μmol/L, 20 μmol/L 2A-1-1 could reduce the PAGmax in normal group by 47.06%) 53.47%)71.52% respectively.Conclusions 1. PAGmax in essential hypertension patients is higher than normal people remarkably, suggesting that the high reactive status of platelets is an important factor for the development of thrombus in hypertension patients.2. Nifedipine has no effects on PAGmax, therefore it can not inhibit platelet aggregation.3.SK and F96365 can reduce the platelet aggregation.4. 2A-1-1 can inhibit platelet aggregation, therefore, it has the definite effect of anti-platelet.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
